Abbott Laboratories reaches a significant $670 million settlement to resolve litigation and over 2,000 claims alleging its infant formula for premature babies triggered necrotizing enterocolitis, a severe intestinal infection. This landmark agreement addresses serious health concerns that emerged regarding the safety profile of specialized nutrition products designed for vulnerable newborn populations. The settlement reflects growing scrutiny of infant formula manufacturers' quality assurance protocols and product safety standards.

Summary auto-generated by AI from the original publisher's content. Editorial standards.